

Review of: "First long-term safety analysis of the ChAdOx1-nCoV-19 corona virus vaccine: results from a prospective observational study in priority vaccinated groups in North India"

Amy Body¹

¹ Monash University

Potential competing interests: No potential competing interests to declare.

Dear authors,

Congrats on this ambitious study.

Some more detail in the paper would help with reader understanding:

1. How do these delayed results differ from the results previously published by you? (reading both papers, it looks like the initial publication was about immediate/acute adverse effects, and the new one is about persistent adverse effects- but this isn't immediately clear in the text of the current paper)
2. Suggest 2 tables of frequencies of AEs- one of immediate and one of delayed/persistent AEs
3. In your table of the logistic regression results- from my reading the 2b analysis only was statically significant for hypothyroidism and previous COVID19. But in the paragraph underneath you suggest all the 2a factors are significant predictors of persistent AESIs- could you please clarify if the 2a analysis refers to any AESI (regardless of persistence) then divide the paragraph below into predictors of any AESI and predictors for persistent AESI
4. It would be good if you could include as supplementary info your case report form so that all data collected can be seen
5. It would be good to compare the rate of hypertension, arthralgia etc to the background incidence in the population locally- it seems to me that particularly the hypertension is probably about what would be expected in a year's follow up of 1500 patients- it would be good to comment on this
6. The discussion overall seems to paint the vaccination in a negative light- is this the intention? Overall the adverse effects you report seem mild, non lifethreatening and also of uncertain aetiology- I think it is important to be careful with wording here. I note your previous paper concluded that vaccination was safe and wonder if your opinion has changed?
7. It would be useful if you could specifically comment on AESI that have been of previous concern with this vaccine e.g. blood clots, Guillain Barre etc- were any cases of these observed?